AML envolving from MDS, MDS-RAEB
Conditions
Interventions
Case series:decitabine with low-dose idarubicin / cytarabine
Sponsors
1st Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adults more than 18 years of age; 2. Patients with a confirmed diagnosis of de novo acute myeloid leukemia (AML) envolving from MDS, or MDS-RAEB-1 acompanied with complex chromosomal aberrations, or MDS-RAEB-2, or patients with AML envolving from MDS / MDS-RAEB received no more than 2 kinds of schemes of first recurrence; 3. Patients with adequate performance status (Eastern Cooperative Oncology Group scale less than 2); 4. Adequate hepato-renal function (creatinine level less than 176umol/l; bilirubin level less than 50umol/L and hepatic enzymes less than twice the upper limit of normal); 5. Patients are required to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients also have other organ malignant tumor; 2. Patient's liver and kidney function was abnormal beyond the inclusion criteria; 3. Patients have serious heart disease, including myocardial infarction, heart function grade 3-4; 4. Known HIV positive serological reaction; 5. Life expectancy is less than 3 months; 6. Patients had received treatment with Vidaza or decitabine, or had received stem cell transplantation; 7. Pregnant or lactating women; 8. The bone marrow biopsy showed low proliferative MDS; 9. Diagnosed with secondary MDS; 10. Participating in other clinical research in the same period; 11. the researchers estimate cannot enter group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission rate after first chemotherapy cycle; | — |
Secondary
| Measure | Time frame |
|---|---|
| partial remission rate;two years overall survival rate; | — |
Contacts
Public ContactHong-yan Tong
Outcome results
None listed